Latest Chronic Pruritus Stories
-- Statistically Significant Data from Phase 2 Study Support Safety and Efficacy of Once Daily Dosing of NK-1 Antagonist, VPD-737 (serlopitant) SOUTH SAN FRANCISCO, Calif., Dec.
CANTERBURY, England, March 21, 2014 /PRNewswire/ -- - Phase 2b data demonstrates a 60% reduction in pruritus in psoriatic patients treated with
- A pivoted catch designed to fall into a notch on a ratchet wheel so as to allow movement in only one direction (e.g. on a windlass or in a clock mechanism), or alternatively to move the wheel in one direction.